

Bio :: Dr. Raoul S. Concepcion, M.D., F.A.C.S.

Raoul S. Concepcion, M.D., F.A.C.S., is the Director of the The Comprehensive Prostate Center in Nashville TN and also a Clinical Assistant Professor in the Department of Urology, Vanderbilt School of Medicine. He is a Past President of the Large Urology Group Practice Association (LUGPA), a non for profit entity representing the interests of over 2500 Urologists in the U.S. affiliated with large single specialty groups.



Dr. Concepcion was a General Surgery and Urology Resident at Vanderbilt University School of Medicine from 1984 – 1989. He served as Chief Urology Resident from 1989 – 1990 and was also a research fellow in the Light Laboratories at Vanderbilt. He has been in practice since 1990, with his major clinical interest being Urologic Oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction, and the role of genomic testing in GU malignancies. He is Board Certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeons and the Nashville Surgical Society. He also serves on the SUO-CTC prostate cancer panel and a reviewer for the Journal of Urology.

From a research perspective, Dr. Concepcion has been actively involved in basic science and clinical research since his days at Vanderbilt. Dr. Concepcion has been either the principal investigator (PI) or Co-PI on many clinical trials since the 1990's. The focus as of recent has been in advanced prostate cancer, as well as biomarker development. Along with 2 other urologists, he recently started CUSP, a Urology specific clinical trials management company, that specializes in site and patient accrual for the pharmaceutical and biolab industries. From an industry perspective, Dr. Concepcion serves as an advisor or consultant for many pharmaceutical companies in the advanced prostate cancer world, including Dendreon, Astellas, Pfizer, Merck, Clovis, Janssen, Invitae, Myriad, Cellay, Siena, Verde Health and CUSP. He also is engaged with many consulting and management firms involved in urological business development.